Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions.

Kubo S, Kadota K, Otsuru S, Hasegawa D, Shigemoto Y, Habara S, Tada T, Tanaka H, Fuku Y, Katoh H, Goto T, Mitsudo K.

EuroIntervention. 2013 Nov;9(7):788-96. doi: 10.4244/EIJV9I7A131.

2.

Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]).

Ko YG, Kim JS, Kim BK, Choi D, Hong MK, Jeon DW, Yang JY, Ahn YK, Jeong MH, Yu CW, Yun KH, Lim DS, Jang Y; KISS Investigators.

Am J Cardiol. 2012 Mar 1;109(5):607-13. doi: 10.1016/j.amjcard.2011.10.014. Epub 2011 Dec 14.

PMID:
22172241
3.

A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.

Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, Hayashi Y, Shiode N, Saito S, Ikari Y, Kimura T, Hosokawa J, Nakamura M, Kotani J, Kozuma K, Mitsudo K.

Am Heart J. 2013 Sep;166(3):527-33. doi: 10.1016/j.ahj.2013.07.002. Epub 2013 Aug 13.

PMID:
24016503
4.

Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.

Takasawa Y, Iijima R, Shiba M, Nakamura M, Sugi K.

J Cardiol. 2010 May;55(3):391-6. doi: 10.1016/j.jjcc.2010.01.003. Epub 2010 Feb 7.

5.

Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure.

Kubo S, Kadota K, Otsuru S, Hasegawa D, Habara S, Tada T, Tanaka H, Fuku Y, Katoh H, Goto T, Mitsudo K.

EuroIntervention. 2015 Jan;10(9):e1-8. doi: 10.4244/EIJV10I9A180.

6.

Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.

Song HG, Park DW, Kim YH, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Han S, Seong IW, Lee NH, Lee BK, Lee K, Lee SW, Nah DY, Park SJ.

J Am Coll Cardiol. 2012 Mar 20;59(12):1093-100. doi: 10.1016/j.jacc.2011.11.047.

7.

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.

Nojima Y, Yasuoka Y, Kume K, Adachi H, Hattori S, Matsutera R, Kohama Y, Sasaki T.

Coron Artery Dis. 2014 Dec;25(8):638-44. doi: 10.1097/MCA.0000000000000159.

8.

One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.

Chevalier B, Moulichon R, Teiger E, Brunel P, Metzger JP, Pansieri M, Carrie D, Stoll HP, Wittebols K, Spaulding C, Fajadet J; Cristal Investigators.

J Interv Cardiol. 2012 Dec;25(6):586-95. doi: 10.1111/j.1540-8183.2012.00769.x. Epub 2012 Sep 20.

PMID:
22994863
9.

Mechanisms of balloon angioplasty and repeat stenting in patients with drug-eluting in-stent restenosis.

Alfonso F, Sandoval J, Pérez-Vizcayno MJ, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Ibáñez B, Núñez-Gil I, Rivero F, Escaned J, Fernández-Ortíz A, Macaya C.

Int J Cardiol. 2015 Jan 15;178:213-20. doi: 10.1016/j.ijcard.2014.10.139. Epub 2014 Oct 23.

PMID:
25464257
10.

Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.

Auffret V, Berland J, Barragan P, Waliszewski M, Bonello L, Delarche N, Furber A, Albert F, Carrié D, Eltchaninoff H, Pansieri M, Schneeberger M, Piot C, Marcollet P, Bedossa M.

Int J Cardiol. 2016 Jan 15;203:690-6. doi: 10.1016/j.ijcard.2015.11.031. Epub 2015 Nov 6.

11.

Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.

Habara S, Kadota K, Shimada T, Ohya M, Amano H, Izawa Y, Kubo S, Hyodo Y, Otsuru S, Hasegawa D, Tada T, Tanaka H, Fuku Y, Goto T, Mitsudo K.

J Am Coll Cardiol. 2015 Jul 7;66(1):14-22. doi: 10.1016/j.jacc.2015.05.002.

12.

Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]).

Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, Martí V, Lozano I, Angel J, Hernández JM, López-Mínguez JR, Melgares R, Moreno R, Seidelberger B, Fernández C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology).

JACC Cardiovasc Interv. 2012 Jul;5(7):728-37. doi: 10.1016/j.jcin.2012.03.017.

13.

Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.

Abdel-Wahab M, Nienaber CA, Mostafa AE, Sabin G, Tebbe U, Hochadel M, Senges J, Akin I, Kuck KH, Hamm C, Richardt G; German Drug-Eluting Stent (DES.DE) registry.

EuroIntervention. 2011 Jun;7(2):201-8. doi: 10.4244/EIJV7I2A34.

14.

Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation.

Tada T, Kadota K, Hosogi S, Miyake K, Ohya M, Amano H, Izawa Y, Kanazawa T, Kubo S, Ichinohe T, Hyoudou Y, Hayakawa Y, Sabbah MM, Otsuru S, Hasegawa D, Habara S, Tanaka H, Fuku Y, Katoh H, Goto T, Mitsudo K.

Eur Heart J Cardiovasc Imaging. 2015 Oct;16(10):1101-11. doi: 10.1093/ehjci/jev031. Epub 2015 Mar 9.

PMID:
25762559
15.

Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.

Almalla M, Schröder J, Pross V, Marx N, Hoffmann R.

Catheter Cardiovasc Interv. 2014 May 1;83(6):881-7. doi: 10.1002/ccd.25072. Epub 2013 Jul 3.

PMID:
23765557
16.

Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention.

Solinas E, Dangas G, Kirtane AJ, Lansky AJ, Franklin-Bond T, Boland P, Syros G, Kim YH, Gupta A, Mintz G, Fahy M, Collins M, Kodali S, Stone GW, Moses JW, Leon MB, Mehran R.

Am J Cardiol. 2008 Aug 1;102(3):311-5. doi: 10.1016/j.amjcard.2008.03.060. Epub 2008 May 24.

PMID:
18638592
17.

Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis.

Zhao L, Zhu W, Zhang X, He D, Guo C.

BMC Cardiovasc Disord. 2017 Jan 6;17(1):16. doi: 10.1186/s12872-016-0445-6.

18.

Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.

Takagi K, Ielasi A, Shannon J, Latib A, Godino C, Davidavicius G, Mussardo M, Ferrarello S, Figini F, Carlino M, Montorfano M, Chieffo A, Nakamura S, Colombo A.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):491-8. doi: 10.1161/CIRCINTERVENTIONS.111.964874. Epub 2012 Jul 31.

19.

Management of drug eluting stent in-stent restenosis: A systematic review and meta-analysis.

Goel SS, Dilip Gajulapalli R, Athappan G, Philip F, Gupta S, Murat Tuzcu E, Ellis SG, Mishkel G, Kapadia SR.

Catheter Cardiovasc Interv. 2016 May;87(6):1080-91. doi: 10.1002/ccd.26151. Epub 2015 Nov 28. Review.

PMID:
26613637
20.

Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials.

Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS.

JACC Cardiovasc Interv. 2015 Mar;8(3):382-94. doi: 10.1016/j.jcin.2014.09.023. Epub 2015 Feb 18.

Supplemental Content

Support Center